Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Inclusion criteria: * Metastatic Hormone Refractory Prostate Cancer (mHRPC) previously treated with a docetaxel-containing regimen * Disease Progression during or after docetaxel-containing regimen for mHRPC * Surgical or medical castration * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2 * Life-expectancy ≥3 months * Adequate bone marrow, liver, and renal function: Neutrophils\> 1500 /mm3; Hemoglobin \> 10 g/dL; Platelets \> 100 x109/L; Bilirubin \< ULN; SGOT (AST) \< 1.5xULN; SGPT (ALT) \< 1.5xULN; Creatinine \< 1.5xULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance \< 60 mL/min should be excluded. Exclusion criteria: * Prior radiotherapy to ≥ 40% of bone marrow * Prior radionuclide therapy (samarium-153, strontium-89, P-32…) * Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment * Active grade ≥2 peripheral neuropathy * Active grade ≥2 stomatitis * Active infection requiring systemic antibiotic or anti-fungal medication * Active cancer (other than mHRPC) including prior malignancy from which the patient has been disease-free for ≤5 years (except superficial basal cell skin cancer) * Known brain or leptomeningeal involvement * History of severe hypersensitivity reaction (≥grade 3) to docetaxel * History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs * History of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisone or prednisolone * Uncontrolled severe illness or medical condition (including uncontrolled cardiac arrhythmias, angina pectoris, hypertension or diabetes mellitus). History of congestive heart failure (NYHA III or IV) or myocardial infarction within last 6 months is also not allowed. * Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450 3A4/5 * Participation in a clinical trial with any investigational drug * Patient with reproductive potential not implementing accepted and effective method of contraception The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.